Docoh
Loading...

AMRX Amneal Pharmaceuticals

News

From Benzinga Pro
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
5 Jan 22
Biotech, News, Penny Stocks, Guidance, Financing, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity
5 Jan 22
Biotech, Long Ideas, M&A, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General
Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development
Amneal Acquires Saol Therapeutics' Baclofen Franchise; Terms Not Disclosed
5 Jan 22
M&A, News, Penny Stocks, Small Cap
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") and Saol Therapeutics, a private specialty pharmaceutical company ("Saol"), today announced a definitive agreement under which Amneal will acquire Saol's Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development.
12 Health Care Stocks Moving In Friday's After-Market Session
17 Dec 21
Movers
TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva
8 Dec 21
Biotech, News, Penny Stocks, Health Care, Small Cap, Legal, General
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
8 Dec 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation
Amneal Pharma Reports Receives Approval For Difluprednate Ophthalmic Emulsion
19 Nov 21
Biotech, News, FDA, General
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
3 Nov 21
Biotech, Earnings, News, Guidance, Health Care, Small Cap, Movers, Trading Ideas, General
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million.
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
3 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap
Here's a roundup of top developments in the biotech space over the last 24 hours.
Amneal Pharmaceuticals Q3 EPS $0.21 Beats $0.20 Estimate, Sales $528.59M Miss $545.06M Estimate
3 Nov 21
Earnings, News
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 31.25 percent increase over earnings of $0.16 per share from
Earnings Scheduled For November 3, 2021
3 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Amneal Pharmaceuticals Granted Tentative Approval For PLERIXAFOR
27 Oct 21
News, FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215334
Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
25 Oct 21
News, Health Care, Small Cap, General
Billionaire investor Mark Cuban is funding a new company focused on selling generic pharmaceuticals at a transparent fixed-rate markup.

Press releases

From Benzinga Pro
Amneal Acquires Saol Therapeutics' Baclofen Franchise
5 Jan 22
Press Releases
- Expands Amneal's Neurology Presence into Spasticity Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal") and Saol Therapeutics, a private specialty pharmaceutical company ("Saol"), today announced a definitive
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
21 Dec 21
Press Releases
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (the "Company") today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at the 40th Annual J.P. Morgan Healthcare Conference on January
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
19 Nov 21
Press Releases
- Represents the latest generic ophthalmic product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA)
Amneal to Virtually Participate at Upcoming Investor Conferences
12 Nov 21
Press Releases
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (the "Company") today announced that its investor relations or management team will virtually attend the following investor conferences: Jefferies London Healthcare
Amneal Reports Third Quarter 2021 Financial Results
3 Nov 21
Press Releases
‒ Q3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21 ‒ ‒ Updating 2021 Full Year Financial
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
2 Nov 21
Press Releases
Reinforcing its commitment to purpose-driven strategy, performance, and culture Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced the release of its inaugural Corporate Responsibility
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
27 Oct 21
Press Releases
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and